SEP 4, 2026 · PHASE 1 TRIAL
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
ClinicalTrials.gov
Phase 1/1b trial registration with no reported results; the study is actively recruiting and designed to evaluate safety and early antitumor activity in a small population.
Reported
Planned enrollment100
Study phasePhase 1/1b
Primary outcome measure (Part A)Incidence and grade of Adverse Events and S…